



MenoGen

Personalized hormonal care.
Guided by genetics.

www.fagrongenomics.com

 **Fagron**
genomics

A growing reality in women's health

Menopause is becoming an increasingly visible topic in healthcare, driven by growing patient awareness and expectations around care.

As more women seek to play an active role in decisions about their health and wellbeing, healthcare professionals are facing new opportunities and challenges in menopause care.



LONG-TERM HEALTH

One-third

Women spend approximately one-third of their lives after menopause.¹



UNMET NEED

Nearly 30%

of women with moderate to severe hot flashes had never received treatment despite access to healthcare.²



SYMPTOM IMPACT

About 25%

of women experience debilitating symptoms during menopause.³



The challenge of hormonal individuality

Menopause is increasingly recognized as a highly individualized experience, with significant differences in symptom burden, treatment response and long-term health considerations.



The conversation around menopause is changing

More women are actively seeking answers, support and personalized solutions for symptoms that were once considered an inevitable part of aging.



**MENOPAUSE?
LIFE DOESN'T PAUSE**

Genetic insights for personalized hormonal care

MenoGen is a genetics-guided clinical approach designed to support healthcare professionals in the personalized management of perimenopausal and menopausal symptoms.

By integrating genetic and clinical information, MenoGen supports more individualized care discussions and therapeutic decision-making.



MENOPAUSE GENETIC INSIGHTS

Related to hormonal balance and long-term women's health.



HORMONAL THERAPY SUPPORT

Guidance on hormone therapy options, including formulation and dosage considerations.



NUTRACEUTICAL SUPPORT OPTIONS

Nutraceutical recommendations based on key hormonal pathways.

What MenoGen analyzes

34 genetic variations across 9 clinically relevant areas:



Estrogen synthesis



Estrogen metabolism 1



Estrogen metabolism 2



Estrogen transport



Cardiovascular



Bone health



Brain health



Folate metabolism



Choline requirements

Genetic insights to complement clinical decision-making.

Learn more about MenoGen.

Fagron
genomics

References:

1. Lobo RA, Gompel A. Management of menopause: a view towards prevention. *Lancet Diabetes Endocrinol.* 2022 Jun;10(6):457-470. doi: 10.1016/S2213-8587(21)00269-2.
2. Kingsberg S, Banks V, Caetano C, Janssenswillen C, Moeller C, Schoof N, et al. Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study. *Maturitas.* 2024 Nov;189:108096. doi: 10.1016/j.maturitas.2024.108096.
3. Lumsden MA, Dekkers OM, Faubion SS, et al. European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. *Eur J Endocrinol.* 2025 Oct;193(4):G49-G81. doi: 10.1093/ajeendo/lvaf206.

LEGAL DISCLAIMER

Fagron Genomics, S.L.U expressly reserves any legal actions in case of an inappropriate, negligent or incorrect use or interpretation of the results of our tests. It is the responsibility of the healthcare professional who requests a test to guarantee to the patient the appropriate genetic advice as foreseen by Law 14/2007, of 3rd July, of biomedical research. As Fagron Genomics, S.L.U does not have access to the personally identifiable information about the patient from whom the sample comes, it is the responsibility of the requesting healthcare professional to comply with the applicable data protection Laws and regulations.

Fagron Genomics, S.L.U carries out genetic tests upon request by healthcare professionals, in relation to biological samples from patients obtained by the healthcare professional. Our tests do not replace a medical consultation, nor do they make up a diagnostic or treatment, nor should they be interpreted this way. Only healthcare professionals can interpret the results of said tests, based on their knowledge of the clinical records of the patients and other relevant factors and, under their responsibility, give a diagnosis or prescribe treatment to the patient. We decline all responsibility derived from the use and interpretation of the results of our tests by the requesting healthcare professional.

FG-RE-MK-091-01-ENG

Fagron Genomics, S.L.U.

C/ de les Cosidores, 150
08226 Terrassa
Barcelona (Spain)
www.fagrongenomics.com

Customer Service:
+34 687876800
+34933801157
HELP@fagrongenomics.com

